HOME
SEARCH
RSS FEED
SUBSCRIBE
Human Cell Lines with Mannosyl Oligosaccharide Glucosidase (MOGS) Defect for the Study and Prevention of Infection
Case ID:
TAB-3665
Web Published:
12/6/2022
Description:
This technology includes human cell lines from patients who have genetic defects in MOGS, the gene encoding mannosyl-oligosaccharide glucosidase, causing the rare congenital disorder of glycosylation type IIb, also known as MOGS-CDG. This defects appears to impair the ability of viruses to infect a second round of cells, which can be used to study and prevent infections. This is likely related to impaired viral replication and cellular entry. This finding has implications for Ebola and Zika, as well as other viral infections.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Human_Cell_Lines_with_Mannosyl_Oligo saccharide_Glucosidase_(MOGS)_Defect_for_the_Study_and_Prevention_of_Infection
Category(s):
Endocrinology
Infectious Disease
Dental
Cardiology
Ophthalmology
Oncology
Research Materials
Bookmark this page
Download as PDF
For Information, Contact:
Eggerton Campbell
Licensing And Patenting Manager
NIH Technology Transfer
301-402-1648
eggerton.campbell@nih.gov
Inventors:
Cynthia Tifft
Sergio Rosenzweig
David Adams
Lynne Wolfe
William Gahl
Keywords:
Cell
Defect
GLYCOPROTEIN
Glycosidase
Human
Lines
Mannosyl
MOG
MOGS
MYELIN
Oligodendrocyte
Olygosaccharide
VLXXXX
VPXXXX
WIXXXX
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum